Business - May 18, 2022
Business Interview: At the forefront of clinical cell therapy
XNK Therapeutics recently secured a private placement of 132 million SEK, enabling progress of the company’s development of new NK cell-based therapies. Since its foundation ten years ago, Swedish XNK Therapeutics has been developing novel autologous natural killer (NK) cell-based therapies targeting cancer. The company’s technology platform includes assets related to the investigational drug product […]
In a new job - May 10, 2022
Ted Fjällman is a new board member at XNK Therapeutics
XNK Therapeutics has announced that Ted Fjällman, Partner at Flerie Invest, has joined the company’s board of directors. Flerie Invest led the SEK 132 million financing of XNK earlier this year by placing SEK 100 million and thus gaining approximately 22 percent of the total number of shares and votes in the company, becoming XNK’s […]
Biotech Business - March 29, 2022
XNK Therapeutics raises 132 million SEK
The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications. The company’s lead investigational candidate drug is currently being evaluated in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) in […]
Clinical Trials - March 23, 2022
First patient treated in XNK Therapeutics study
XNK Therapeutics has announced that the first patient has been treated in a Phase II clinical study using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab). “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical development […]
Clinical Trials - February 21, 2022
XNK Therapeutics phase I study published
XNK Therapeutics has announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible, states the company. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following […]
In a new job - November 22, 2021
XNK Therapeutics adds three scientific advisors
XNK Therapeutics has announced the strengthening of the company’s expertise by the appointment of Ola Landgren, Fredrik Schjesvold and Johan Lund. These scientific advisors are key to the company’s plan to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies, the company […]
